Breaking News
Sort by:
Top Post
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen, a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, and […]
Trinity Capital Provides $25 Million Growth Capital To RxAnte
Trinity Capital, a leading provider of diversified financial solutions to growth-stage companies, has announced a […]
Mestag Therapeutics Appoints Professor Ton Logtenberg as Chair
Mestag Therapeutics, an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory […]
KKR to Acquire Bushu Pharmaceuticals
KKR, a leading global investment firm, and Bushu Pharmaceuticals have announced the signing of definitive […]
Scorpion Biological Services Becomes Scorpius BioManufacturing to Reflect Expansion
Scorpion Biological Services has announced it has changed its name to Scorpius BioManufacturing reflecting the […]
CN Bio Appoints Dr Paul Brooks as Chief Executive Officer
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems […]
XtalPi and EDDC Collaborate in AI-empowered Drug Discovery Program for Non-Small Cell Lung Cancer
XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, has announced […]
Eiger BioPharmaceuticals Announces Leadership Change
Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis […]
CenSyn and HonorHealth Announce Strategic Partnership
CenSyn, a digital telehealth company advancing portable screening of brain health-related conditions via its platform […]
Gilgamesh Pharmaceuticals Raises $39 Million in Series B Funding to Advance Mental Health Treatments
Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression […]
PhoreMost and ThinkCyte Collaborate to Advance AI Based Drug Discovery
PhoreMost, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more